07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

Bepotastine besilate nasal spray: Phase II data

Top-line data from a placebo-controlled, double-blinded U.S. Phase II trial in 600 patients with allergic rhinitis due to Mountain Cedar pollen showed that each of 3 dosages of bepotastine nasal spray twice daily met the...
08:00 , Dec 20, 2010 |  BC Week In Review  |  Clinical News

Bepotastine besilate nasal spray: Phase II started

Ista began a placebo-controlled, U.S. Phase II trial to evaluate twice-daily bepotastine besilate nasal spray for 2 weeks in about 600 patients with allergic rhinitis due to Mountain Cedar pollen. Ista has exclusive North American...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

Bepotastine besilate nasal spray: Preliminary Phase I/II data

Preliminary data from a double-blind, Canadian Phase I/II trial in 82 patients exposed on multiple occasions to high aerosol concentrations of a common seasonal allergen to which they were sensitive showed that mid- and high-dose...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

Bepotastine besilate nasal spray: Phase I/II started

Ista began a placebo-controlled Phase I/II trial to evaluate bepotastine nasal spray given twice daily in 96 patients in an environmental exposure chamber. Last year, FDA approved an NDA from Ista for Bepreve bepotastine...